<DOC>
	<DOCNO>NCT00325117</DOCNO>
	<brief_summary>This study conduct United States . Vildagliptin oral antidiabetic agent . This 12-week clinical study design multicenter , randomize , double-blind , parallel-group , placebo-controlled study aim evaluate efficacy safety vildagliptin add-on therapy sulfonylurea patient type 2 diabetes inadequately control sulfonylurea monotherapy .</brief_summary>
	<brief_title>To Assess Efficacy Safety Vildagliptin Add-on Therapy Sulfonylurea Patients With Type 2 Diabetes Inadequately Controlled With Sulfonylurea Monotherapy</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<criteria>Diagnosis type 2 diabetes treat stable dose sulfonylurea Patients diet exercise reach target blood glucose level Outpatients Type 1 diabetes , diabetes result pancreatic injury , secondary form diabetes Significant cardiovascular complication define protocol Significant diabetic complication define protocol Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2007</verification_date>
	<keyword>Type 2 diabetes</keyword>
	<keyword>Vildagliptin</keyword>
	<keyword>HbA1c</keyword>
</DOC>